Evidence map›Paper›PMID 42911273›Full record

ReviewCancer metastasis reviews2026

Before the seeds arrive: pre-metastatic niche orchestration in bladder cancer.

Da-Ming Xu, Ming Li, Hao Lin, Xiao-Yu Zhuang, Hui Han, Wei He, Zhen-Yu Ou

Abstract readReview
PubMed Publisher
In one paragraph

Review in Cancer metastasis reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Da-Ming Xu *Department of Urology, Second Affiliated Hospital of Shantou University Medical College, Shantou, 515041, P. R. China.
Ming Li *Department of Urology, Second Affiliated Hospital of Shantou University Medical College, Shantou, 515041, P. R. China.
Hao Lin *Department of Urology, Second Affiliated Hospital of Shantou University Medical College, Shantou, 515041, P. R. China.
Xiao-Yu Zhuang *Department of Anesthesiology, Second Affiliated Hospital of Shantou University Medical College, Shantou, 515041, P. R. China.
Hui HanState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, P. R. China. hanhui@sysucc.org.cn.
Wei HeDepartment of Urology, Xiangya Hospital, Central South University, Changsha, 410008, P. R. China. xy_heweidoctor@163.com.
Zhen-Yu OuDepartment of Urology, Xiangya Hospital, Central South University, Changsha, 410008, P. R. China. ouzhenyu1@csu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metastatic relapse remains a major cause of mortality in bladder cancer (BCa), yet the biological processes that prepare distant organs for tumor colonization before overt metastasis remain incompletely understood. The pre-metastatic niche (PMN) provides a framework for viewing metastasis as a systemic process in which tumor-derived signals reshape distant immune, stromal, vascular, lymphatic, and metabolic environments before cancer-cell arrival. In BCa, some of the strongest disease-specific evidence implicates extracellular vesicle (EV)-mediated communication, including effects on lymphangiogenesis, vascular permeability, myeloid suppression, stromal crosstalk, and metabolic reprogramming. Additional contributions from myeloid-derived suppressor cells, macrophages, fibroblasts, neutrophil extracellular traps, chemokine networks, and metabolic adaptation may further promote niche permissiveness, although direct BCa evidence remains uneven across mechanisms and metastatic organs. Organotropism to lymph nodes, lung, liver, and bone may reflect the convergence of tumor-intrinsic programs, EV surface molecules, chemokine gradients, and tissue-specific receptivity. Clinically, PMN-associated biomarkers could complement minimal residual disease (MRD) assessment by integrating ctDNA with plasma and urinary EVs and immune, stromal, and metabolic signals. However, such approaches remain investigational and require prospective validation. This review critically evaluates current BCa-specific and cross-cancer evidence, highlights key mechanistic and translational gaps, and proposes a hypothesis-generating MRD-PMN framework for future surveillance and metastatic-interception studies.

Indexed as

Tumor MicroenvironmentUrinary Bladder NeoplasmsAnimalsExtracellular VesiclesHumansNeoplasm MetastasisBladder cancerExtracellular vesicleMetastasisPre-metastatic nicheTumor microenvironment

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.